Nolvadex-D (Tamoxifen Citrate)

Tamoxifen citrate, the active ingredient in Nolvadex-D, is a selective estrogen receptor modulator (SERM) presented as an oral formulation for systemic use. It is employed in the management of estrogen‑receptor positive breast cancer and for chemoprevention in women at high risk of developing the disease.

GNH USA supplies Nolvadex-D as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Tamoxifen citrate acts on estrogen‑dependent pathways and is indicated for several breast‑related conditions.

- Estrogen receptor‑positive breast cancer: reduces recurrence and improves survival in adjuvant and metastatic settings. - Ductal carcinoma in situ (DCIS): limits progression to invasive disease after surgery. - High‑risk women: provides chemoprevention to lower the incidence of breast cancer.

Tamoxifen citrate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Nausea or vomiting: mild to moderate gastrointestinal upset. - Menstrual irregularities: changes in cycle length or flow. - Fatigue: generalized tiredness. - Mild rash or skin irritation.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism: signs of clotting. - Endometrial cancer: abnormal uterine bleeding. - Severe liver dysfunction: jaundice or elevated enzymes. - Visual disturbances: blurred vision or retinal changes. - Severe allergic reaction: swelling, hives, or difficulty breathing.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks.

- Thromboembolic risk: assess history of clotting disorders before use. - Endometrial monitoring: perform regular gynecologic exams for abnormal bleeding. - Liver function: check baseline enzymes and repeat periodically. - Pregnancy and lactation: avoid use in pregnant or nursing women unless clearly indicated. - Drug interactions: review concomitant medications for CYP2D6 inhibitors. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and direct sunlight.

Tamoxifen citrate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may markedly reduce tamoxifen efficacy. - Warfarin: increased anticoagulant effect, necessitating INR monitoring. - Aromatase inhibitors: concurrent use offers no added benefit and may increase toxicity.

Moderate Interactions (Monitor Closely): - SSRIs with weak CYP2D6 inhibition (e.g., sertraline): monitor therapeutic response. - Antacids or proton pump inhibitors: may affect absorption; separate dosing by at least 2 hours. - Herbal supplements (e.g., St. John’s wort): potential induction of metabolism, watch for reduced effectiveness.